About this trial

The recent development and market introduction of small diameter implantable defibrillation leads able to deliver left bundle branch area pacing (LBBAP) has opened the possibility of achieving cardiac resynchronization therapy (CRT) using a single- or dual-chamber implantable-cardioverter defibrillator (ICD). This approach may reduce the number of intracardiac leads required and, consequently, has the potential to lower both procedural and long-term complication rates. However, the integration of these leads into currently recommended CRT strategies remains hypothetical. The FORGE CSP registry will prospectively enroll patients with an indication for CRT in whom implantation of a LBBAP ICD lead is attempted.

Eligibility criteria

Qualifiers

age > 18-year-old

indication for CRT according to current ESC/EHRA guidelines

first-line LBBAP ICD lead implantation attempted

national insurance coverage

Disqualifiers

pregnancy

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

1
Caen University Hospital Caen France

Sponsors and collaborators

University Hospital, Caen

Lead sponsor